New antiviral approaches for human parainfluenza: Inhibiting the haemagglutinin-neuraminidase.
Sign Up to like & getrecommendations! Published in 2019 at "Antiviral research"
DOI: 10.1016/j.antiviral.2019.04.001
Abstract: Human parainfluenza viruses cause acute respiratory tract infections and disease predominantly in young children and immunocompromised individuals. Currently, there are no vaccines to prevent hPIV infections, nor licensed anti-hPIV drugs. There is therefore a need… read more here.
Keywords: human parainfluenza; new antiviral; haemagglutinin neuraminidase; antiviral approaches ... See more keywords
Targeting Some Enzymes with Repurposing Approved Pharmaceutical Drugs for Expeditious Antiviral Approaches Against Newer Strains of COVID-19
Sign Up to like & getrecommendations! Published in 2021 at "AAPS PharmSciTech"
DOI: 10.1208/s12249-021-02089-5
Abstract: At present, global vaccination for the SARS-CoV2 virus 2019 (COVID-19) is 95% effective. Generally, viral infections are arduous to cure due to the mutating nature of viral genomes, with the consequent quick development of resistance,… read more here.
Keywords: approved pharmaceutical; strains covid; antiviral approaches; pharmaceutical drugs ... See more keywords